Chirec

Chirec’s respiratory department employs cutting‑edge imaging and biomarker platforms to refine diagnosis and guide treatment decisions.

• Evaluation of HER2 PET/CT imaging for metastatic breast cancer and other solid tumors
• Assessment of PD‑L1 testing methods to select immunotherapy candidates
• Development of advanced respiratory monitoring tools for early detection of lung disease

The department leverages state‑of‑the‑art equipment to improve early detection and personalize therapeutic strategies.

Clinical studies at the site focus on preventing pregnancy‑related complications and improving reproductive outcomes.

• Low‑dose acetylsalicylic acid for reducing preeclampsia risk in women undergoing frozen embryo transfer
• Investigation of frozen embryo transfer outcomes and associated maternal health metrics
• Evaluation of maternal‑fetal safety parameters in early‑stage clinical interventions

Collaboration with obstetrics specialists ensures comprehensive care and robust safety monitoring.

The hospital conducts research aimed at enhancing bone healing and addressing challenging orthopedic conditions.

• Safety and efficacy of autologous 3D osteogenic implant NVD‑003 for recalcitrant lower‑limb nonunion
• Evaluation of novel bone regeneration techniques to accelerate fracture repair
• Assessment of functional recovery and quality of life after orthopedic surgery

Integrated orthopedic expertise enables rapid translation of innovative bone‑repair solutions.

A broad oncology portfolio at Chirec targets lung, breast, rectal and other solid cancers with a focus on personalized therapies.

• Targeted therapy trials for EGFR‑mutated non‑small cell lung cancer
• Combination regimens for HER2‑positive metastatic breast cancer
• Immunotherapy approaches for PD‑L1‑expressive NSCLC
• Neoadjuvant strategies in locally advanced rectal cancer
• Investigation of KRAS G12C inhibitors across lung cancer subtypes
• Novel treatments for triple‑negative breast cancer

Multidisciplinary teams work together to improve survival rates and reduce treatment‑related toxicity.

Research at the site examines how environmental exposures influence respiratory health and informs public‑health strategies.

• Study of air‑quality impacts on asthma exacerbations in urban populations
• Assessment of occupational hazards related to lung disease among workers
• Population‑based surveillance of respiratory infection trends

Findings contribute to evidence‑based policies aimed at reducing environmental risk factors.

Additional trials span neonatal care, dose‑optimization studies and rare disease investigations, reflecting the site’s versatile research capacity.

• Safety and efficacy of doxapram for preventing apnea of prematurity
• Dose‑optimization studies for emerging therapeutic agents in oncology
• Exploratory endpoints in rare disease cohorts to generate early efficacy signals

The flexible trial design enables rapid inclusion of innovative studies across multiple therapeutic domains.